Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Regulation of Stroke Volume01:27

Regulation of Stroke Volume

3.3K
The regulation of stroke volume, which is the amount of blood the heart pumps out during each heartbeat, is critical for maintaining a healthy circulatory system. Stroke volume is influenced by three main factors: preload, contractility, and afterload.
Preload refers to the degree of stretch on the heart before it contracts. It's analogous to the stretching of a rubber band; the more it's stretched, the more forcefully it snaps back. This concept is encapsulated in the Frank-Starling law of the...
3.3K
Ischemic Heart Disease: Overview01:17

Ischemic Heart Disease: Overview

1.4K
Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
1.4K
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

225
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
225
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

205
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
205
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

16
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
16
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

354
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
354

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Delayed identification and treatment of a cervicomedullary spinal vascular lesion following angiogram-negative, high-grade subarachnoid hemorrhage: illustrative case.

Journal of neurosurgery. Case lessons·2026
Same author

Oncolytic viruses enhance CAR-T activity for the treatment of pediatric diffuse midline gliomas.

Molecular therapy. Oncology·2026
Same author

Mitochondrial stress response drives microglial senescence.

Nature neuroscience·2026
Same author

Impact of infratentorial location on survival after surgical resection of brain metastases: a multicenter retrospective study.

Neuro-oncology advances·2026
Same author

Machine learning-guided multimodal profiling defines perturbed immune states at the time of cancer diagnosis.

Briefings in bioinformatics·2026
Same author

Leveraging neuroscience imaging and electrophysiological assessments to decode neuron-glioma interactions.

Neuro-oncology advances·2026
Same journal

Correction: Jiménez-Sánchez et al. Antioxidant Enzymes Genetic Variants Associated with Urticaria/Angioedema Induced by Cross-Reactive Hypersensitivity to Nonsteroidal Anti-Inflammatory Drugs. <i>Pharmaceuticals</i> 2026, <i>19</i>, 522.

Pharmaceuticals (Basel, Switzerland)·2026
Same journal

Correction: Zhao et al. Multifunctional Gel Films of Marine Polysaccharides Cross-Linked with Poly-Metal Ions for Wound Healing. <i>Pharmaceuticals</i> 2022, <i>15</i>, 750.

Pharmaceuticals (Basel, Switzerland)·2026
Same journal

Intravenous Immunoglobulin Reveals a Novel Protective Mechanism: Targeting the GBP5-Driven Pyroptosis Axis in Experimental Colitis.

Pharmaceuticals (Basel, Switzerland)·2026
Same journal

Icariin Attenuates Renal Injury in Streptozotocin-Induced Diabetic Rats with and Without Adenine-Induced Chronic Kidney Disease.

Pharmaceuticals (Basel, Switzerland)·2026
Same journal

AI-Assisted Identification of a Putative Allosteric Ligand Targeting the CDK4/Cyclin D1 Protein-Protein Interface.

Pharmaceuticals (Basel, Switzerland)·2026
Same journal

Development and Study of Hydrophilic Ointment Compositions with a Dextrin/Polyvinyl Alcohol/Iodine Complex (D/PVA/I).

Pharmaceuticals (Basel, Switzerland)·2026
See all related articles

Related Experiment Video

Updated: Jul 29, 2025

Author Spotlight: Establishing a Reliable Distal MCA Occlusion Model in Mice for Stroke Research
07:34

Author Spotlight: Establishing a Reliable Distal MCA Occlusion Model in Mice for Stroke Research

Published on: December 15, 2023

2.2K

SUMOtherapeutics for Ischemic Stroke.

Paramesh Karandikar1, Jakob V E Gerstl2, Ari D Kappel2,3

  • 1T. H. Chan School of Medicine, University of Massachusetts, Worcester, MA 01655, USA.

Pharmaceuticals (Basel, Switzerland)
|May 27, 2023
PubMed
Summary
This summary is machine-generated.

The small, ubiquitin-like modifier (SUMO) pathway shows neuroprotective effects, offering a promising therapeutic target for acute cerebral ischemia. Small molecules targeting SUMOylation are being validated in preclinical models.

Keywords:
SUMOylationexperimental therapeuticsischemianeuroprotectionstroke

More Related Videos

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke
09:21

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke

Published on: January 18, 2018

12.1K
A Thrombotic Stroke Model Based On Transient Cerebral Hypoxia-ischemia
06:01

A Thrombotic Stroke Model Based On Transient Cerebral Hypoxia-ischemia

Published on: August 18, 2015

14.9K

Related Experiment Videos

Last Updated: Jul 29, 2025

Author Spotlight: Establishing a Reliable Distal MCA Occlusion Model in Mice for Stroke Research
07:34

Author Spotlight: Establishing a Reliable Distal MCA Occlusion Model in Mice for Stroke Research

Published on: December 15, 2023

2.2K
Optimized Management of Endovascular Treatment for Acute Ischemic Stroke
09:21

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke

Published on: January 18, 2018

12.1K
A Thrombotic Stroke Model Based On Transient Cerebral Hypoxia-ischemia
06:01

A Thrombotic Stroke Model Based On Transient Cerebral Hypoxia-ischemia

Published on: August 18, 2015

14.9K

Area of Science:

  • Neuroscience
  • Molecular Biology
  • Biochemistry

Background:

  • The small, ubiquitin-like modifier (SUMO) pathway regulates key biological processes, including the mammalian stress response.
  • SUMOylation has demonstrated neuroprotective effects, notably observed in hibernating squirrels.
  • Its role in neuronal ischemia, ion gradients, and neural stem cell preconditioning highlights therapeutic potential.

Purpose of the Study:

  • To review current knowledge on the SUMOylation pathway in the context of brain ischemia.
  • To highlight the translational potential of targeting SUMOylation for acute cerebral ischemia treatment.

Main Methods:

  • Literature review summarizing existing research on SUMOylation and cerebral ischemia.
  • Discussion of findings from high-throughput screening and preclinical models.

Main Results:

  • SUMOylation is implicated in managing neuronal responses to ischemia.
  • Small molecules that upregulate SUMOylation have been identified and validated in preclinical models.
  • The SUMO pathway plays a role in maintaining ion gradients and neural stem cell preconditioning.

Conclusions:

  • The SUMOylation pathway is a promising therapeutic target for acute cerebral ischemia.
  • Further research and development of SUMOylation-targeting molecules could lead to novel treatments for brain ischemia.